The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial
Abstract
IMPORTANCE: Whether the administration of luteinizing hormone-releasing hormone analogues (LHRHa) during chemotherapy is a reliable strategy to preserve ovarian function is controversial owing to both the lack of data on long-term ovarian function and pregnancies and the safety concerns about the potential negative interactions between endocrine therapy and chemotherapy. OBJECTIVE: To evaluate long-term results of LHRHa-induced ovarian suppression during breast cancer chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: Parallel, randomized, open-label, phase 3 superiority trial conducted at 16 Italian sites. Between October 2003 and January 2008, 281 premenopausal women with stage I to III hormone receptor-positive or hormone receptor-negative breast cancer were enrolled. Last annual follow-up was June 3, 2014. INTERVENTIONS: Patients were randomized to receive adjuvant or neoadjuvant chemotherapy alone (control group) or chemotherapy plus triptorelin (LHRHa group). MAIN OUTCOMES AND MEASURES: The primary planned end point was incidence of chemotherapy-induced early menopause. Post hoc end points were long-term ovarian function (evaluated by yearly assessment of menstrual activity and defined as resumed by the occurrence of at least 1 menstrual cycle), pregnancies, and disease-free survival (DFS). RESULTS: A total of 281 women (median age, 39 [range, 24-45] years) were randomized. Median follow-up was 7.3 years (interquartile range, 6.3-8.2 years). The 5-year cumulative incidence estimate of menstrual resumption was 72.6% (95% CI, 65.7%-80.3%) among the 148 patients in the LHRHa group and 64.0% (95% CI, 56.2%-72.8%) among the 133 patients in the control group (hazard ratio [HR], 1.28 [95% CI, 0.98-1.68]; P = .07; age-adjusted HR, 1.48 [95% CI, 1.12-1.95]; P = .006). Eight pregnancies (5-year cumulative incidence estimate of pregnancy, 2.1% [95% CI, 0.7%-6.3%]) occurred in the LHRHa group and 3 (5-year cumulative incidence estimate of pregnancy, 1.6% [95% CI, 0.4%-6.2%]) in the control group (HR, 2.56 [95% CI, 0.68-9.60]; P = .14; age-adjusted HR, 2.40 [95% CI, 0.62-9.22]; P = .20). Five-year DFS was 80.5% (95% CI, 73.1%-86.1%) in the LHRHa group and 83.7% (95% CI, 76.1%-89.1%) in the control group (LHRHa vs control: HR, 1.17 [95% CI, 0.72-1.92]; P = .52). CONCLUSIONS AND RELEVANCE: Among premenopausal women with either hormone receptor-positive or hormone receptor-negative breast cancer, concurrent administration of triptorelin and chemotherapy, compared with chemotherapy alone, was associated with higher long-term probability of ovarian function recovery, without a statistically significant difference in pregnancy rate. There was no statistically significant difference in DFS for women assigned to triptorelin and those assigned to chemotherapy alone, although study power was limited. TRIAL REGISTRATION: clinicaltrials.gov Identifier:NCT00311636.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Badawy, A., Elnashar, A., El-Ashry, M., & Shahat, M. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.12.044 · Cited by 331
RetractedHoward-Anderson, J., Ganz, P. A., Bower, J. E., & Stanton, A. L. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr541 · Cited by 830
Cited by
Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update
Oktay, K., Harvey, B. E., Partridge, A. H., Quinn, G. P., Reinecke, J., Taylor, H. S., Wallace, W. H., Wang, E. T., & Loren, A. W. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.1914 · Cited by 1,486
Cancer and fertility preservation: international recommendations from an expert meeting
Lambertini, M., Del Mastro, L., Pescio, M. C., Andersen, C. Y., Azim, H. A., Peccatori, F. A., Costa, M., Revelli, A., Salvagno, F., Gennari, A., et al. (2016) · BMC Medicine · doi:10.1186/s12916-015-0545-7 · Cited by 781
Self-citationGonadotropin-Releasing Hormone and Its Analogues
Kovacs, P. (2020) · Textbook of Assisted Reproduction · doi:10.1007/978-981-15-2377-9_8 · Cited by 422
Lambertini, M., Moore, H. C. F., Leonard, R. C. F., Loibl, S., Munster, P., Bruzzone, M., Boni, L., Unger, J. M., Anderson, R. A., Mehta, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.0858 · Cited by 393
Self-citationClinical practice guideline on pregnancy and renal disease
Wiles, K., Chappell, L., Clark, K., Elman, L., Hall, M., Lightstone, L., Mohamed, G., Mukherjee, D., Nelson-Piercy, C., Webster, P., et al. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1560-2 · Cited by 275
Metadata
- Authors
- Lambertini, M., Boni, L., Michelotti, A., Gamucci, T., Scotto, T., Gori, S., Giordano, M., Garrone, O., Levaggi, A., Poggio, F., Giraudi, S., Bighin, C., Vecchio, C., Sertoli, M. R., Pronzato, P., Del Mastro, L., & for the GIM Study Group
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-12-22
- Volume
- 314
- Issue
- 24
- Pages
- 2632
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2220296590
- Cited by
- 205
- References
- 2
- FWCI
- 28.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2015.17291
- The paper
- Lambertini, M., Boni, L., Michelotti, A., Gamucci, T., Scotto, T., Gori, S., Giordano, M., Garrone, O., Levaggi, A., Poggio, F., Giraudi, S., Bighin, C., Vecchio, C., Sertoli, M. R., Pronzato, P., Del Mastro, L., & for the GIM Study Group. (2015). Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2015.17291
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.